Davis Group

Polymer science expertise targeted at nanomedicine applications

The Davis group led by Prof. Tom Davis is world renowned for polymer science expertise targeted at nanomedicine applications. We are focused on the smart design of nanoparticles for theranostic applications, with specific interest in pathological paradigms of protein aggregation and controlling the involvement of gut-microbiota in mediating the associated pathogenesis. The misfolding and fibrillar aggregation of proteins is responsible for onset and progression of different neurological disorders such as Alzheimer’s and Parkinson’s diseases and metabolic diseases like type-2-diabetes, and we aim to understand and mitigate this using nanoscience.

The Davis group is developing pharmaceutical excipients of nanomedicine that can target diseases by identifying intracellular targets. The future of therapeutics must consider the multi-pathogenic complexity of diseases that will lead to the concept of identifying the causes of disease rather than targeting symptom management as currently in clinical practice. This is possible by taking a broader perspective of etiology of disease processes and understanding the silent molecular-linkages from underlying conditions such as gut-infections and ulcers.

Researchers